Spero Therapeutics
Cambridge
About Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $100K – $500K
- Total funding: $443.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2022)
- Ticker: nasdaq:SPRO
- Website: sperotherapeutics.com
- Phone: +1 857 242 1600
Industries & Categories
Biotechnology, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/spero-therapeutics-53552 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.